Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

businesswire.com
DMAC The article announces DiaMedica Therapeutics' participation in the Jefferies Global Healthcare Conference. It provides details about the presentation but does not offer any new information regarding the company's performance or prospects.

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 MINNEAPOLIS--( BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026.

Jefferies Global Healthcare Conference

Date: Thursday, June 4, 2026

Time: 3:45 PM ET

Format: Corporate Presentation

If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.